Boosting Theranostic Performance of AIEgens Using Nanocatalyzer for Robust Cancer Immunotherapy

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(23)

Published: Feb. 15, 2024

Abstract High‐performance theranostic systems are of paramount importance for achieving precise image‐guided cancer immunotherapy. Here, a novel nanoplatform is presented that integrates aggregation‐induced emission luminogen (AIEgen) with prussian blue (PB) nanocatalyzer robust The AIEgen dimethylamine substitution demonstrates compelling near‐infrared (NIR) light‐induced photothermal conversion and photodynamic therapy (PDT) capabilities. By incorporating into porous PBNPs, further enveloped within M1 macrophage membrane, tumor‐specific nanoagent constructed. This strategic integration effectively constrains the molecular motion AIEgen, leading to amplified NIR‐II fluorescence brightness PDT attributes. Moreover, PBNPs can catalyze tumor‐overexpressed H 2 O generate oxygen boost efficacy, PB's NIR absorption also intensifies photoacoustic imaging effect. provides comprehensive information photoimmunotherapy in orthotopic breast cancer‐bearing mice. Leveraging its potent immunogenic cell death effect, not only significantly inhibits growth, but generates whole‐cell therapeutic vaccine protect mice from tumor rechallenge. In highly malignant post‐surgery models, enables both accurate identification residual tumors efficient inhibition postoperative recurrence pulmonary metastasis. study will offer valuable insights creating efficacious multifaceted protocols.

Language: Английский

---

Traditional Chinese medicine in lung cancer treatment

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 26, 2025

Lung cancer remains a major global health challenge and one of the leading causes cancer-related deaths worldwide. Despite significant advancements in treatment, challenges such as drug resistance, side effects, metastasis recurrence continue to impact patient outcomes quality life. In response, there is growing interest complementary integrative approaches care. Traditional Chinese medicine (TCM), with its long history, abundant clinical experience, holistic perspective individualized approach, has garnered increasing attention for role lung prevention management. This review provides comprehensive overview advances TCM covering theoretical foundation, treatment principles, experiences evidence supporting efficacy. We also provide systematic summary preclinical mechanisms, through which impacts cancer, including induction cell death, reversal inhibition modulation immune responses. Additionally, future prospects are discussed, offering insights into expanded application integration modern address this challenging disease.

Language: Английский

---

Ultrasmall Enzyodynamic PANoptosis Nano‐Inducers for Ultrasound‐Amplified Hepatocellular Carcinoma Therapy and Lung Metastasis Inhibition

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(45)

Published: Sept. 3, 2024

Abstract Addressing the inefficiency of current therapeutic approaches for hepatocellular carcinoma is an urgent and pressing challenge. PANoptosis, a form inflammatory programmed cell death, presents dependable strategy combating cancer by engaging multiple death pathways (apoptosis, pyroptosis, necroptosis). In this study, ultrasmall Bi 2 Sn O 7 nanozyme with ultrasound‐magnified multienzyme‐mimicking properties designed engineered as PANoptosis inducer through destroying mitochondrial function tumor cells enhancing intracellular accumulation toxic reactive oxygen species, finally triggering activation process. The role has been verified expression related proteins, including cleaved Caspase 3, NLRP3, N‐GSDMD, 1, p‐MLKL, RIPK3. inclusion external ultrasonic irradiation significantly augments enzyodynamic efficiency. vitro in vivo antineoplastic efficacy, along inhibition lung metastasis, validate benefits ‐mediated pathway. This study not only elucidates intricate mechanisms underlying inducer, but also offers novel perspective treatment carcinoma.

Language: Английский

---

Monitoring ROS Responsive Fe₃O₄‐based Nanoparticle Mediated Ferroptosis and Immunotherapy via ¹²⁹Xe MRI

Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(22)

Published: March 29, 2024

The immune checkpoint blockade strategy has improved the survival rate of late-stage lung cancer patients. However, low response limits immunotherapy efficiency. Here, we report a ROS-responsive Fe

Language: Английский

---

Ti3C2Tx MXene quantum dots coated hollow manganese dioxide nanoparticles for tumor combination therapy and magnetic resonance imaging

Materials Today Chemistry, Journal Year: 2024, Volume and Issue: 39, P. 102171 - 102171

Published: June 24, 2024

Language: Английский

---

Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor

Materials Today Bio, Journal Year: 2024, Volume and Issue: 26, P. 101029 - 101029

Published: March 19, 2024

Multi-drug resistance (MDR) in advanced breast cancer (ABC) is triggered by the high expression of P-glycoprotein (P-gp), which reduces intracellular concentration anti-tumor drugs, turn preventing oxidative stress damage to cytoplasmic and mitochondrial membranes. It therefore clinical relevance develop P-gp-specific targeted nanocarriers for treatment drug resistant ABC. Herein, a carrier targeting CD44 mitochondria was synthesised delivery encequidar (ER, P-gp inhibitor) paclitaxel (PTX). HT@ER/PTX nanoparticles (ER:PTX molar ratio 1:1) had excellent inhibition ability induce apoptosis MCF-7/PTX cells vitro. Furthermore, showed more efficacy than PTX (Taxol®) xenograft mouse model cells; tumor inhibitory rates Taxol® were 72.64% ± 4.41% 32.36% 4.09%, respectively. The survival tumor-bearing mice administered prolonged compared that treated with Taxol®. In addition, not only inhibited P-gp-mediated removal toxic lipid peroxidation byproducts resulting from drugs but also upregulated dynamics-related protein, fostering damage, induced activation Caspase-3 pathway. Our findings indicate co-delivery inhibitors could be practical approach treating multi-drug

Language: Английский

---

Biomimetic nanosystems harnessing NIR-II photothermal effect and hypoxia-responsive prodrug for self-amplifying and synergistic tumor treatment

Nano Today, Journal Year: 2024, Volume and Issue: 57, P. 102395 - 102395

Published: July 8, 2024

Language: Английский

---

Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives

Small Methods, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Non‐small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development novel multi‐functional nanomedicines the realm tumor offers promising opportunities for NSCLC patients, as exhibit advantages, including specific targeting cells, improved drug bioavailability, reduced systemic toxicity, and overcoming immune resistance. In this review, core features current status strategies checkpoint blockade, antibody–drug conjugates, engagers, adoptive vaccines, are surveyed. Particular emphasis is placed on recent that boost these strategies. Nanomedicine can provide perspectives immunotherapy.

Language: Английский

---

A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 250, P. 114557 - 114557

Published: Feb. 9, 2025

Language: Английский

---

Current and future therapies for small cell lung carcinoma

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 1, 2025

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation and high metastatic potential. It universal inactivation of RB1, overexpression the MYC family dysregulation multiple oncogenic signaling pathways. Among different patients, SCLCs are similar at genetic level but exhibit significant heterogeneity molecular level. The classification SCLC has evolved from a simple neuroendocrine (NE)/non-neuroendocrine (non-NE) system to transcription factor-based subtype system; lineage plasticity adds further complexity poses challenges for therapeutic development. While initially sensitive platinum-based chemotherapy, resistance develops rapidly, leading dismal prognosis. Various antibodies, including PD-1/PD-L1 inhibitors antibody‒drug conjugates, have been introduced into clinical practice or being evaluated in trials. However, their benefits patients remain limited. This review summarizes carcinogenic mechanisms, tumor heterogeneity, immune microenvironment SCLC, with focus on recent advances metastasis mechanisms. Additionally, corresponding progress tackling these discussed.

Language: Английский

---